Pharming Group NV, a biopharmaceutical company based in the Netherlands, announced its quarterly earnings results on October 26, 2023. The company reported an earnings per share (EPS) of $0.01 for the quarter, significantly surpassing analyst estimates. Pharming generated revenue of $106.50 million, exceeding the anticipated $89.72 million.
The company achieved a return on equity of 1.12% and recorded a net margin of 0.71%. Following the announcement, Pharming’s stock opened at $1.51 on Friday. The stock’s performance has remained varied, with a 50-day moving average of $1.77 and a 200-day moving average of $1.62. Over the past 52 weeks, the stock has fluctuated between a low of $0.79 and a high of $2.17. Additionally, Pharming’s financial metrics include a current ratio of 3.16, a quick ratio of 2.39, and a debt-to-equity ratio of 0.46.
About Pharming Group
Founded in 1988 and headquartered in Leiden, Pharming Group specializes in the development and commercialization of protein replacement therapies for rare diseases. The company leverages transgenic technology to produce recombinant proteins, with its leading product being RUCONEST, a recombinant C1 esterase inhibitor designed for treating acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe, and several other regions through partnerships with prominent specialty pharmaceutical companies.
Beyond its flagship product, Pharming has a diversified pipeline aimed at addressing unmet needs in rare and ultra-rare disorders. As the company continues to innovate, it remains committed to providing therapeutic solutions for patients facing these challenging conditions.
Investors and stakeholders can stay updated on Pharming Group’s ongoing developments by subscribing to MarketBeat.com’s free daily email newsletter, which offers concise summaries of the latest news and analysts’ ratings related to the company.
